Connect with us

Hi, what are you looking for?

Friday, Mar 24, 2023
Mugglehead Magazine
Alternative investment news based in Vancouver, B.C.


PHCO2 launches potent and patented ‘Aquazome’ CBD extract

The company claims the new product will revolutionize CBD efficacy and bioavailability

PHCO2 launches potent new 'Aquazome' CBD extract with high bioavailability
Photo via PHCO2.

A Massachusetts extract producer has crafted a new product that it claims is far superior to the vast majority of others in the industry for various reasons.

On Tuesday, PHCOannounced the launch of Aquazome, a water-soluble extract designed to be used for multiple applications including beverages, horse and pet supplies, edibles, capsules, tablets, CBD tinctures and lotions.

PHCOclaims that Aquazome contains a 35 per cent concentration of CBD, yielding a far greater potency than several other products in the market that generally have about a 10-20 per cent ratio of the cannabinoid.

The company also says pharmacokinetics studies have shown that the product has an 80 per cent absorption rate while other competing technologies have merely a fraction of that.

Read more: Green Thumb set to launch ‘RISE Express’ pot shops in Florida next year

Read more: Hemp Inc. raises cultivar yielding high-grade protein in its leaves

Other allegedly superior characteristics of Aquazome include true water solubility compared to other extracts that are only water dispensable/dispersable and higher bioavailability.

The new product is GMP compliant and has been crafted with USDA-certified organic material in a kosher-certified facility, according to the company.

“We are thrilled, once again, to be on the forefront of the CBD industry as we take this leap ahead with another innovation. Water soluble CDB ingredients will allow customers higher bioavailability per serving and deeper efficacy,” said William Smart, business development manager for the company.

“We have over 30 years of experience producing a variety of botanical emulsions, and work closely with customers in the design and development of an emulsion for each application to help ensure comparability in each product.”


Follow Mugglehead on Twitter

Like Mugglehead on Facebook







Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like


'SANA-013' is a proprietary therapy intended to treat conditions like migraines, episodic cluster headaches and MDD

Stock News

The company is planning an internal reorganization to meet the eligibility criteria and minimum requirements for listing


An independent study in B.C. found concerning numbers and pot sold in other provinces was also found to be mislabelled


The state's House of Representatives approved the legislation on Thursday